VEGF inhibitor (Bevacizumab) plus EGFR inhibitor (erlotinib) significantly improved progression-free survival (PFS) in patients with untreated metastatic EGFR-mutated NSCLC [58]. The gene discussed is VEGFA; the disease is non-small cell lung carcinoma.